Patents Examined by Nicole Kinsey
  • Modified orthopoxvirus vectors
    Patent number: 11802292
    Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: October 31, 2023
    Assignees: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.
    Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
  • Compositions and methods for generating an immune response to hepatitis B virus
    Patent number: 11801299
    Abstract: The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: October 31, 2023
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael P. McCurley, Rahul Basu, Ming Luo
  • Attenuated virus mutated at sites of evolutionarily conserved RNA structure
    Patent number: 11795440
    Abstract: Attenuated viruses and methods of designing them are disclosed. In one embodiment, there is disclosed an attenuated form of a virulent virus comprising an RNA encoding a viral protein or a nucleic acid sequence transcribable to said RNA, wherein the folding energy or structure of the RNA is changed at positions of evolutionarily conserved RNA structures with respect to that of said RNA encoding said viral protein in the virulent virus so as to bring about attenuation of the virus.
    Type: Grant
    Filed: September 5, 2021
    Date of Patent: October 24, 2023
    Assignees: RAMOT AT TEL-AVIV UNIVERSITY LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD., SYNVACCINE LTD.
    Inventors: Tamir Tuller, Eli Goz, Shimshi Atar, Hadas Zur
  • Targeted neoepitope vectors and methods therefor
    Patent number: 11779637
    Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and/or a viral expression system for use as a therapeutic agent.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 10, 2023
    Assignee: NantCell, Inc.
    Inventor: Kayvan Niazi
  • Markers of active HIV reservoir
    Patent number: 11781193
    Abstract: Embodiments disclosed herein provide a pan-tissue cell atlas of healthy and diseased subjects obtained by single cell sequencing. The present invention discloses novel markers for cell types. Moreover, genes associated with disease, including HIV infection and tuberculosis are identified. The invention provides for diagnostic assays based on gene markers and cell composition, as well as therapeutic targets for controlling immune regulations and cell-cell communication of the cell types disclosed herein. In addition, novel cell types and methods of quantitating, detecting and isolating the cell types are disclosed.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: October 10, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Alexander K. Shalek, Carly Ziegler
  • Bispecific antibody against rabies virus, and application thereof
    Patent number: 11773155
    Abstract: The present application provides a bispecific antibody against rabies virus, and an application thereof. The bispecific antibody comprises two antigen-binding fragments binding to different epitopes of G protein of rabies virus, and has rabies virus neutralization activity.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: October 3, 2023
    Assignees: Beijing Wisdomab Biotechnology Co., ltd, GENRIX (Shanghai) Biopharmaceutical Co., Ltd., Chongqing GENRIX Biopharmaceutical Co., Ltd.
    Inventors: Zhigang Liu, Xiaobo Hao, Yulan Liu, Jingjing Guo
  • Cleaving pre-fusion state SARS-CoV-2 spike protein
    Patent number: 11746142
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: September 5, 2023
    Assignee: ABCLONAL SCIENCE, INC.
    Inventors: Yang Xiang, Yan Tan
  • Phage-based detection of borreliosis and means therefor
    Patent number: 11739388
    Abstract: This invention relates to methods of detecting Borrelia burgdorferi sensu lato or for detecting Borrelia associated with Relapsing Fever (RF), kits for carrying out such methods, and methods of treating Borrelia burgdorferi sensu lato or RF infections in a subject. Uses of phage specific for Borrelia are also provided.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 29, 2023
    Assignees: UNIVERSITY OF LEICESTER, PHELIX RESEARCH AND DEVELOPMENT LIMITED
    Inventors: Martha Rebecca Jane Clokie, Jinyu Shan, Louis Charles Teulieres
  • SOD1 dual expression vectors and uses thereof
    Patent number: 11739330
    Abstract: In some aspects, the disclosure relates to compositions and methods useful for inhibiting SOD1 expression in cells (e.g., cells of a subject). In some embodiments, the disclosure describes isolated nucleic acids engineered to express an inhibitory nucleic acid targeting endogenous SOD1 and an mRNA encoding a hardened SOD1 protein. In some embodiments, compositions and methods described by the disclosure are useful for treating Amyotrophic Lateral Sclerosis (ALS) in a subject.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 29, 2023
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Robert H. Brown
  • Tymovirus virus and virus-like particles as nanocarriers for imaging and therapeutic agents
    Patent number: 11739301
    Abstract: A method of targeting cancer tissue in a subject includes administering to the subject a plurality of functionalized Tymovirus virus or virus-like particles loaded with or conjugated to an imaging agent, a therapeutic agent or a targeting agent.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 29, 2023
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole F. Steinmetz, Hema Masarapu, He Hu
  • Computational reduction vaccine for Covid-19 originating from Civet Sars, Bat Sars, BetaCov btrs, BetaCov BtRI, and Neoromicia
    Patent number: 11735301
    Abstract: A vaccine candidate is herein described comprised by statistically significant DNA fragments related to Civet SARS, Bat Sars, and BtRs BetaCov, BtRI BetaCov, and Neoromicia resulting in three types of compositions: 1) a composition of statistically significant DNA fragments, 2) a composition of RNA transcripts corresponding to the statistically significant DNA fragments, and 3) a computational reduction composition wherein the DNA fragments are fully or partially subtracted from a base organism, resulting in a synthetic organism which has a high statistical likelihood of problematic functions being partially or fully removed.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: August 22, 2023
    Inventor: Matthew Vernon Hanson
  • Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
    Patent number: 11730823
    Abstract: Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 22, 2023
    Assignee: President and Fellows of Harvard College
    Inventor: Quan Lu
  • T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides
    Patent number: 11702461
    Abstract: The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide that exhibits reduced binding affinity to a cognate co-immunomodulatory polypeptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: July 18, 2023
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Rational polyploid adeno-associated virus vectors for the treatment of disease
    Patent number: 11702676
    Abstract: The present invention provides a polyploid adeno-associated virus (AAV) capsid, wherein the capsid comprises capsid protein VP1, wherein said capsid protein VP1 is from one or more than one first AAV serotype, wherein said capsid protein VP2 is from one or more than one first AAV serotype and capsid protein VP3, wherein said capsid protein VP3 is from one or more than one second AAV serotype and wherein at least one of said first AAV serotype is different from at least one of said second AAV serotype and is different from at least one of said third AAV serotype, in any combination.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: July 18, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Chengwen Li, Richard Jude Samulski
  • Adenoviral vectors comprising partial deletions of E3
    Patent number: 11702675
    Abstract: This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: July 18, 2023
    Assignee: The Wistar Institute
    Inventors: Hildegund C. J. Ertl, Xiang Yang Zhou
  • Anti-bacterial compositions and uses thereof
    Patent number: 11690885
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: July 4, 2023
    Assignee: PHERECYDES PHARMA
    Inventors: Cindy Fevre, Hélène Blois, Mathieu Medina
  • Bacteriophage-based electrochemical bacterial sensors, systems, and methods
    Patent number: 11686729
    Abstract: The present disclosure includes methods and systems of detecting bacteria in a sample using phage-functionalized sensors, methods of enriching a sample with phage-functionalized magnetic particles, phage-functionalized magnetic particles and methods of making phage-functionalized magnetic particles.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: June 27, 2023
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Ramaraja P. Ramasamy, Yan Zhou
  • Engineered cells with decreased gene expression resulting in increased viral production
    Patent number: 11655471
    Abstract: Disclosed are compositions and methods for increasing virus production. In particular, disclosed herein are cell or cell line comprises reduced expression of one or more cellular genes selected from the group comprising COQ9, FGF2, NAT9, NDUFA9, NEU2, PLA2G1B, PYCR1, RAD51AP1, STRADA, SVOPL, and/or ZFYVE9 for use in increasing viral production.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 23, 2023
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Ralph A Tripp
  • Human immunodeficiency virus neutralizing antibodies
    Patent number: 11655285
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: May 23, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Antigen purification
    Patent number: 11655461
    Abstract: Disclosed herein are methods and exemplary compositions associated with antigen purification, exemplary aspects of which may include harvesting viral and antigenic substances from source organisms; and a purification platform comprising chemical separation and size-difference separation for the removal of contaminants, debris and impurities from the viral and protein (e.g. antigenic, including influenza hemagglutinin antigens) substances, as well as their concentration and collection.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 23, 2023
    Assignee: KBIO HOLDINGS LIMITED
    Inventors: Steven D. Hume, Leigh Burden, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, John W. Shepherd, Kelsi Swope